Exosome Therapy For Hair Loss: How It Works And What The Evidence Shows
Last reviewed on 24 July 2026. We review our treatment guides every six months to keep them accurate.
Key points
Exosomes are membrane packages released by cells, roughly 100 to 200 nanometres across, carrying proteins, lipids and microRNA. They act as a messaging system that lets one cell change another cell's behaviour.
The proposed mechanism for hair loss is that exosomes deliver the instructions the dermal papilla normally uses to switch a follicle into its growth phase, mainly by activating Wnt and beta-catenin signalling, and by suppressing the TGF-beta pathway through which DHT drives follicle miniaturisation.
In animals the results are striking. In a 2017 study in Scientific Reports, stem cell derived vesicles produced full regrowth in mice by day 27, matching 3 per cent minoxidil.
In people, every published study so far reports improvement. The larger of the two randomised trials, in 85 patients over 12 weeks, reported hair density rising by 35 hairs per square centimetre against 3 in the placebo group, though it appears in a journal that is not indexed by PubMed.
The better documented randomised trial is much smaller and its result more modest: 20 men over 16 weeks, with a median gain of 9.5 hairs against 1.5 on placebo.
The evidence base is small and inconsistent. A 2025 systematic review found 11 clinical studies covering 298 patients in total, only two of which were randomised controlled trials, using different products and protocols that cannot reliably be compared.
Reported side effects in those studies were mild and temporary, mainly scalp redness and irritation, with no serious systemic reactions recorded across all 298 patients.
No exosome product is licensed as a medicine in the UK. A search of the electronic Medicines Compendium returns no results for exosomes.
Exosomes of human origin are banned in cosmetic products sold in the UK, according to the Department for Business and Trade.
Exosome treatments are sold across the UK for hair loss, usually as a course of injections into the scalp or as a serum applied during microneedling. They are among the most discussed ideas in hair restoration, and unlike much of what gets marketed for hair loss, the science behind them is real rather than invented.
This guide covers what exosomes are, how they are supposed to work, what the laboratory and human studies have actually found, what the safety record looks like, and where UK law stands, which is not where most clinic websites imply.
Regulatory positions on new biological treatments change. For the current UK position, check the Medicines and Healthcare products Regulatory Agency (MHRA) directly.
What are exosomes?
Exosomes are tiny membrane packages released by cells, typically 100 to 200 nanometres across. They carry proteins, lipids and fragments of genetic material, in particular short strands called microRNAs.
Their significance is that they turned out not to be cellular waste, which is what they were once assumed to be. Exosomes are a messaging system. A cell packages a set of instructions into an exosome, releases it, and a neighbouring cell absorbs it and changes its behaviour in response. This allows one cell to reprogramme another without the two ever touching.
Products sold as exosomes differ enormously in origin. Some are derived from plants or from salmon, others from human cells such as umbilical cord blood, placenta, bone marrow or fat derived mesenchymal stem cells. That distinction matters commercially, scientifically and, in the UK, legally.
Why is the idea taken seriously?
The appeal of exosomes is that they promise the benefits of stem cell therapy without the cells. The approach grew directly out of stem cell research.
The attraction of stem cells was always the helpful signals they release. The problem was the cells themselves. Living cells introduced into a patient can be rejected, can behave unpredictably, are difficult to store, and are extremely difficult to manufacture to a consistent standard. Much of the regulatory caution around stem cell clinics stems from those risks.
Exosomes offer, in principle, the signal without the cell. Nothing living is transferred, so there is no cell that can be rejected or misbehave. A preparation could in theory be manufactured in batches, characterised, stored and used off the shelf, which is closer to how a conventional medicine works than a cell therapy could ever be. That is a genuinely elegant idea, and it is why serious academic laboratories, not only cosmetic clinics, are working on it.
How are exosomes supposed to make hair grow?
The proposed mechanism is that exosomes deliver the chemical instructions a follicle uses to switch itself back into growth. Understanding it requires knowing what controls the hair cycle.
A hair follicle does not grow continuously. It cycles between a growth phase called anagen, a brief regression phase called catagen, and a resting phase called telogen, after which the hair sheds and the cycle restarts. In male and female pattern hair loss, dihydrotestosterone (DHT) acting on genetically susceptible follicles progressively shortens the growth phase and miniaturises the follicle, so hairs emerge finer, shorter, and eventually not at all.
The structure controlling that cycle is a small cluster of cells at the base of the follicle called the dermal papilla. The dermal papilla is the instructive part of the follicle: it tells the surrounding stem cells when to start growing a hair. Its importance is demonstrated by a quirk of laboratory work, which is that dermal papilla cells lose their hair inducing ability when grown in a dish for too many generations. Early passage cells can trigger follicle formation and late passage cells cannot, despite looking much the same.
Exosomes appear to be a substantial part of how the dermal papilla issues those instructions. That reframes the therapeutic question: rather than transplanting dermal papilla cells, which is difficult, the proposition is to deliver the messages they send.
Three signalling routes recur throughout the research:
The Wnt and beta-catenin pathway. This is the best established molecular switch for the growth phase of the hair cycle. When it is active, dermal papilla cells and follicle stem cells proliferate and the follicle enters anagen. Across a large number of studies, exosomes from various sources raise beta-catenin levels in follicle cells.
MicroRNA cargo. The active ingredient appears to be the genetic instructions inside the exosome rather than the package itself. One well cited example is miR-218-5p, which works by suppressing SFRP2, a natural brake on the Wnt pathway, so the growth signal is released indirectly.
The TGF-beta and SMAD pathway. This is the route that connects exosomes to pattern hair loss specifically. TGF-beta1 is a signal associated with a follicle shutting down and entering regression, and it is part of how DHT drives miniaturisation. Certain exosomal microRNAs suppress that pathway, which is the proposed basis for the claim that exosomes could counteract DHT rather than merely stimulate growth in general.
Some studies also report increases in growth factors such as VEGF and IGF-1, which are associated with the blood supply and growth signalling a follicle needs during anagen.
The mechanism is coherent. It is not a marketing invention, and it targets a real and relevant part of hair follicle biology.
What did the laboratory studies find?
The preclinical results are striking, and they are the reason the field attracts serious attention.
In a 2017 study published in Scientific Reports, extracellular vesicles from mesenchymal stem cells increased dermal papilla cell proliferation and raised VEGF and IGF-1 in cells taken from hair transplant patients. Injected into mice, the same preparation produced darkening of the skin at day 11, indicating follicles had entered the growth phase, more than 60 per cent hair regrowth by day 18, and fully regrown fur by day 27. Its effect matched 3 per cent minoxidil, used as the comparison treatment.
In a 2020 paper in Science Advances, exosomes taken from dermal papilla cells grown as three dimensional spheroids, a method that better preserves their hair inducing character, contained 25 times more miR-218-5p than exosomes from conventionally cultured cells, and promoted hair regeneration in mice through the beta-catenin route described above.
One limitation governs how far those results can be carried. Both studies, and the great majority like them, were conducted in mice and in cultured cells rather than in living humans. The standard mouse experiment involves shaving or depilating young mice so their hair cycles start together, then measuring how quickly fur returns. That tests whether a substance can accelerate a normal, healthy, synchronised hair cycle. It does not test whether it can reverse years of DHT driven miniaturisation on a human scalp, which is the problem an actual patient has.
Does exosome therapy work in people?
Every published human study of exosomes for hair loss reports an improvement, and several report substantial ones. This is the part of the picture most sceptical write ups leave out, so it is worth setting out in detail before assessing how much weight it can carry.
A systematic review published in Clinical, Cosmetic and Investigational Dermatology in 2025 identified 11 clinical studies published between 2022 and 2025, covering 298 patients in total. The main findings were as follows.
The two randomised controlled trials. The larger, by Nadeem and colleagues in 2024, treated 85 patients over 12 weeks with exosomes from fat derived mesenchymal stem cells. It reported an increase in hair density of 35 hairs per square centimetre against 3 in the placebo group, from a baseline of about 100, and an increase in hair thickness of about 13 micrometres, with patient satisfaction averaging 8.5 out of 10. One caveat belongs with that figure: the trial appears in the Journal of Population Therapeutics and Clinical Pharmacology, which is not indexed in PubMed, so it has not passed through the indexing checks that most of the literature cited on this page has.
The second randomised trial is smaller but better documented. Amini and colleagues, published in Life in 2025, ran a placebo controlled trial in 20 men over 16 weeks using a plant derived preparation containing Ecklonia cava and Thuja orientalis extracts. The treatment group gained a median of 9.5 hairs against 1.5 in the placebo group, a statistically significant difference with a large effect size, and no notable adverse effects. The authors declared no conflicts of interest.
The non randomised studies. The figures below are as tabulated in the 2025 systematic review rather than from the original papers. Gentile and colleagues followed 60 patients for 12 months and reported density gains of 28 hairs per square centimetre in women and 30 in men, with 80 per cent of patients satisfied. Park and colleagues in South Korea reported a gain of 24.9 hairs per square centimetre in 39 patients over 12 weeks. A 2024 study by Lee and colleagues followed 30 patients for 24 weeks and reported a more modest rise, from about 158 to 166 hairs per square centimetre. Sasaki and colleagues reported density increases of roughly 11 to 24 per cent in 31 patients over six months.
To put those numbers in context, the scalps in these studies started at roughly 100 to 160 hairs per square centimetre, so a gain of 30 would be a change most people would notice. Whether that gain is real is a separate question from whether it was measured.
How good is that evidence?
The results are encouraging but the evidence supporting them is weak, for four specific reasons rather than as a general complaint.
Almost none of it is randomised, and the largest trial is the least well documented. Of 11 studies, only two were randomised controlled trials, the design that guards against wishful thinking, and one of those included just 20 people. The systematic review's own assessment was direct: "Only two randomized controlled trials were identified, and these had relatively small sample sizes, reducing the strength of the evidence base." There is an awkward pattern in those two: the trial reporting the largest benefit is the one in a journal not indexed by PubMed, while the trial with the fuller published methods and a declared absence of conflicts reported a considerably smaller gain in 20 people. For comparison, the medicines licensed for hair loss in the UK were assessed in trials involving thousands of participants followed for years.
The results are wildly inconsistent. Reported gains range from about 8 hairs per square centimetre over 24 weeks in one study to a rise from 96.5 to 163.5 hairs per square centimetre in just six weeks in another. A near doubling of density in six weeks is difficult to reconcile with the known speed of the hair cycle, in which a follicle takes months to produce visible growth. That spread is not explained by biology alone, and it suggests differences in measurement technique as much as in treatment effect.
The studies cannot be compared with each other. They used exosomes from fat, placenta, bone marrow, umbilical cord, hair follicle, foreskin and plant sources, delivered by injection or by microneedling, over durations from six weeks to 12 months. As the review put it: "The lack of standardized dosing, frequency, and administration methods for exosome therapy presents challenges for clinical reproducibility and generalizability." A good result with one preparation says very little about the product a particular clinic stocks.
No study reports failure. Every published study found a positive result. In a young field with small single arm studies, that pattern usually reflects publication bias, the tendency for disappointing results never to be written up, rather than a treatment that works every time.
A 2024 narrative review in Regenerative Therapy summarised the position as "still in the early stages of research and development" while noting that preclinical and early clinical results have been promising.
So the honest answer is not that exosomes have been shown not to work. Early human results are genuinely positive. They have simply not yet been tested in the way that would establish whether the effect is real, how large it is, how long it lasts, or which preparation delivers it. Several treatments discussed elsewhere on this site sit at a similar stage: the PP405 follicle activator, hair cloning and copper peptides are all areas where early findings have run ahead of confirmation.
Is exosome therapy safe?
In the published studies the safety record is good. Across all 11 clinical studies and 298 patients, the 2025 systematic review reported that adverse events were "predominantly mild and transient, including scalp irritation, redness, swelling, itching, and occasional headaches", and that no serious systemic side effects, infections or immune reactions were recorded.
That record deserves to be stated plainly, because it is more reassuring than the general tone of coverage suggests. It also comes with two limits. Follow up in these studies was short, mostly 12 weeks to 12 months, so long term risks remain insufficiently studied. And the studies used characterised preparations under research conditions, which is not necessarily what a commercial clinic is injecting.
The theoretical concerns are about the product rather than the procedure, and they are the reason regulators are cautious.
The most specific is contamination. Viruses are almost exactly the same size as exosomes and share their physical properties, which makes separating them extremely difficult. Dr Guillaume van Niel, a research director at the Angers Cancer and Immunology Research Centre in Nantes, told the Guardian in March 2025: "The most dangerous risk would be that viruses are in the product. Viruses have the same size and the same physical properties as exosomes. It's nearly impossible to sort exosomes out of a pool of viruses. If you isolate one, you get the other."
Dr James Edgar, a cell biologist at the University of Cambridge whose research focuses on exosomes, raised the related point about human derived material: "These are human biologics and there's a risk for disease transmission." He also noted an uncertainty that follows from the same science that makes exosomes interesting. If the mechanism is that these packages instruct cells to grow, that instruction is not necessarily selective about which tissue receives it.
Van Niel offered the most useful single caution in the subject: "I've been working on exosomes for 25 years, I'm one of the pioneers of the field and we still don't know exactly what exosomes are."
Manufacturing is a further question. Producing genuine exosomes at scale is technically demanding, batch to batch variability is a recognised problem, and in an unregulated market there is no straightforward way for a patient, or a clinic, to confirm a vial contains what the label claims.
One consequence of unlicensed status is worth spelling out. A licensed medicine carries a patient information leaflet listing known side effects and a route for reporting new ones. An unlicensed exosome preparation carries no such leaflet, so there is no agreed side effect list and no systematic collection of problems. Cost is unregulated too, varies widely between clinics, and there is no NHS route to the treatment.
What happened when regulators looked at this?
In December 2019 the United States Food and Drug Administration issued a public safety notification after "multiple recent reports of serious adverse events experienced by patients in Nebraska who were treated with unapproved products marketed as containing exosomes". The notification, issued with the Centers for Disease Control and Prevention and the Nebraska Department of Health and Human Services, stated that "there are currently no FDA-approved exosome products", and that exosomes used to treat conditions in humans are regulated as drugs and biological products subject to premarket review.
The distinction between those harms and the clean safety record in the clinical studies is important. The Nebraska cases involved unapproved commercial products used outside any trial. The published studies used characterised preparations under research conditions. That contrast is essentially the argument for regulation, and it is also the reason a good safety record in a journal does not automatically transfer to a product bought privately.
The FDA is a United States regulator and its rules do not apply in Britain, so this is context rather than UK law.
Is exosome therapy legal in the UK?
Exosome products fall under two different UK regimes depending on how they are sold, and conflating them causes most of the confusion.
As a cosmetic. Exosomes of human origin are prohibited in cosmetic products sold in the UK. Asked about clinics offering these treatments, a Department for Business and Trade spokesperson said: "Exosomes of human origin are banned in cosmetics that are sold in the UK." Reporting by the Guardian in March 2025 found UK clinics advertising treatments using exosomes described as harvested from consenting human donors or derived from umbilical cord blood, which would breach UK and EU rules. Products derived from plant or salmon sources are not caught by that prohibition.
As a medicine. An exosome product injected to treat a condition is not a cosmetic. A 2025 review of the global regulatory landscape records that the MHRA classifies extracellular vesicle therapies as biological medicinal products, with the advanced therapy medicinal product framework applying where they derive from manipulated cells. Products in that category require authorisation before they can be marketed.
A search of the electronic Medicines Compendium, the register of medicines licensed for UK use, returns no results at all for exosomes. There is no licensed exosome medicine in the UK, for hair loss or anything else.
A patient offered exosome therapy for hair loss in the UK is therefore being offered either a cosmetic product that must not be of human origin, or an unlicensed medicine. Neither has been assessed by a UK regulator for treating hair loss.
What to ask if a clinic offers you exosome therapy
What is the product called, who manufactures it, and what is it derived from? A clear answer of plant, salmon or human origin should be available immediately, because in the UK it determines legality.
Is it being sold to me as a cosmetic or administered as a medicine? If it is injected, ask what authorisation it holds.
What human evidence exists for this specific product, as opposed to exosomes as a general idea, and was it a randomised trial?
How will the result be measured, and against what baseline? Density measured properly at the same spot is very different from before and after photographs.
What is the alternative? Treatments with a licensed status and a larger evidence base exist, and a clinic unwilling to compare its offer against them is telling you something.
It is also worth knowing where exosomes sit relative to better established options. Platelet rich plasma uses a preparation made from your own blood on the day, which avoids the donor and contamination questions entirely, though its own evidence base has real limitations. Microneedling is frequently the delivery method used alongside an exosome serum and has been studied in its own right, so where the two are sold together it is fair to ask how much of any benefit is attributable to the needling. Mesotherapy is another scalp-injection treatment, most studied in its dutasteride form, and sits at a similarly early stage of evidence.
Where does this leave things?
Exosome therapy is a serious area of research resting on a plausible mechanism, impressive animal results, and early human studies that are consistently positive. It may well become a licensed treatment.
It is not one yet. The human evidence amounts to 11 studies and fewer than 300 patients with only two randomised trials, the reported effects vary too widely to be explained by biology alone, no exosome medicine is licensed in the UK, and human derived exosomes are banned in cosmetics sold here. A patient paying for exosome therapy today is buying a promising but unproven treatment, without the protections a licensed medicine carries.
Anyone weighing up a hair transplant should discuss any additional treatment, including exosomes, with their own surgeon before booking or paying for it, since it may affect timing and aftercare. Your clinic can tell you what it does and does not offer, and why.
Frequently asked questions
Is exosome therapy for hair loss legal in the UK?
It depends what is in it and how it is sold. Exosomes of human origin are banned in cosmetic products sold in the UK. An exosome product injected to treat hair loss would be a medicine, and no exosome medicine holds a UK licence, so it would be unlicensed. Products derived from plants or salmon are not covered by the cosmetics prohibition on human material, though that does not mean they have been shown to work.
How are exosomes supposed to make hair grow?
The dermal papilla, a cluster of cells at the base of the follicle, controls when a follicle grows, and it appears to issue many of its instructions using exosomes. Delivering those messages is intended to switch follicles back into their growth phase, mainly by activating the Wnt and beta-catenin pathway, and in some research by suppressing the TGF-beta signalling through which DHT drives follicles to shut down.
Do exosomes regrow hair?
Early human results are positive, with a caveat about where they were published. The larger randomised trial, in 85 patients, reported hair density rising by 35 hairs per square centimetre against 3 on placebo, but it appears in a journal not indexed by PubMed. The better documented randomised trial, in 20 men over 16 weeks, found a more modest median gain of 9.5 hairs against 1.5 on placebo. Other studies report gains of roughly 25 to 30 hairs per square centimetre. Only two of the 11 published studies were randomised, the reported effects vary widely, and no study has yet reported a negative result, which suggests publication bias. The effect may be real, but it has not been established to the standard required of a licensed medicine.
Are exosomes the same as PRP?
No. Platelet rich plasma is made from a sample of your own blood, spun down and injected back the same day, so nothing from a donor or a manufacturer is introduced. Exosome products are manufactured preparations derived from other cells, whether plant, animal or human. The safety questions about donor material and contamination apply to exosomes and not to PRP.
What are the side effects of exosome hair treatment?
In published studies, side effects were mild and temporary: scalp irritation, redness, swelling, itching and occasional headaches, with no serious systemic reactions reported across 298 patients. That record comes from short studies using characterised research preparations. Because no exosome product is licensed in the UK, a commercial preparation carries no patient information leaflet and no agreed side effect list, so the true rate outside research conditions is unknown.
Is it safe to have exosome treatment abroad?
Regulation differs by country, and a treatment being available somewhere does not mean it has been assessed there. If you are considering it overseas, find out what regulatory review the specific product has had in that country, and bear in mind that if something goes wrong the follow up care and legal position are unlikely to be straightforward. UK regulators have no oversight of treatments given abroad.
Should I have exosome therapy before or after a hair transplant?
Speak to your own surgeon before arranging anything. Some clinics offer additional treatments around a transplant and others do not, and guidance varies between surgeons, so there is no single answer that applies to everyone. What matters is that your surgeon knows about anything you are having done to your scalp, because it can affect the timing of surgery and your aftercare instructions.
Get back to Great Hair
in 3 Easy Steps:
01
Arrange Free Consultation
Speak to one of our specialist consultants for expert advice on our range of different hair loss treatments
02
Book Your Procedure
Place a deposit to reserve a time slot at one of the My Hair UK clinics across the UK
03
Attend Your Surgery
Arrive on the day and our specialist surgical team will look after your every need
